The dual role of IL-6, both as an indicator of tumor-related inflammation and a predictor of COVID-19 adverse outcomes, suggests that targeting the IL-6 pathway might offer therapeutic benefits in this patient population. This evidence concerns the gene IL6 and COVID-19.